Middle meningeal artery embolization for migraine headaches - a prospective self-control cohort trial
Abstract
BACKGROUND: Migraines are a leading cause of long-term disability. A neurovascular cause of migraines localizing to the middle meningeal artery (MMA), a branch of the external carotid artery, is believed to be a potential underlying mechanism given its anatomical connection to the dura.
MATERIALS AND METHODS: We conducted a self-control pilot study of 15 participants with migraine headaches. All patients were recruited in 2024 and were followed for 90 days post-MMA embolization (MMAE). The inclusion criteria used in the study included men and women with age of 18-80 years with migraine with or without aura, intractable migraine with a disease duration of more than 3 months and migraine attacks > 8 times/month in the past 90 days before enrollment: poor response to two or more medications, or intolerable side effects, or the presence of contraindications to medical therapy. MMAE was achieved with coils, and the side of MMAE chosen by the side of symptom predominance. Migraine severity and disability scoring scales were used pre-embolization and three months post-embolization.
RESULTS: 329 individuals were screened, and 15 patients were enrolled in the study. There were significant improvements in multiple migraine severity and disability scores, including days of headache a month (Z = - 2.938, P = .003), NRS score (Z = - 3.436, P = 0.001), VAS score (t = 6.085, P<0.001), VRS score (Z = - 4.064, P<0.001), MSQ (t = 4.706, P<0.001), HIT6 (t = 4.730, P<0.001, and MIDAS disability…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 329 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.